Cidara Therapeutics Achieves Enrollment Goal for Phase 3 ANCHOR Trial

Trial Enrollment: Cidara Therapeutics has completed target enrollment of 6,000 participants for its Phase 3 ANCHOR trial in the US and UK, focusing on high-risk populations for seasonal influenza complications.

CD388 Evaluation: The trial assesses the safety and efficacy of CD388, a non-vaccine preventative for influenza, administered as a one-time 450-milligram subcutaneous dose to adults and adolescents.

Interim Analysis: An interim analysis is scheduled for the first quarter of 2026 to evaluate trial size and determine if additional enrollment is needed during the Southern Hemisphere flu season.

Regulatory Potential: If successful, results from this Phase 3 trial may support a Biologics License Application (BLA) approval for CD388 in the high-risk populations studied.